AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation

Recruitingn/aAges 18 Years - anyAllOslo University Hospital
💬

In plain words

What the trial is, and whether it could suit you

Heart failure and atrial fibrillation are two of the most common heart diseases globally. Nearly half of all patients with heart failure also have atrial fibrillation. When heart failure and atrial fibrillation occur together, the risk of hospitalization and premature death increases significantly. However, there is a lack of reliable tools to assess how severely the heart is affected in these patients. This makes it difficult both to establish the correct diagnosis, tailor treatment, and predict who is at greatest risk of hospital admission or death from the disease. One of the most important targets in heart failure is the filling pressure in the left ventricle. When this pressure is high, it means that the heart has difficulty receiving blood, leading to shortness of breath and fluid retention in the body. Today, filling pressure is usually estimated using ultrasound (echocardiograph

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Atrial fibrillation (paroxysmal, persistent, or permanent) * Scheduled for RHC or LHC for clinical reasons * Able to undergo echocardiography and invasive pressure measurement within 8 hours * No cardiovascular medication changes between echo and catheterization * Written informed consent provided Exclusion Criteria: * Mitral stenosis or mitral annular calcification causing severe functional stenosis * Severe mitral or severe tricuspid regurgitation * Prosthetic mitral valve * Atrial fibrillation with rapid ventricular response \>120 bpm * Suboptimal echocardiographic imaging * Conditions rendering PCWP or LVEDP unreliable * Pregnant women * Complex congenital heart disease * LV assist device and patients with severe non-cardiac disease with poor prognosis * Cardiac transplant patients * End-stage liver disease
💊

What it tests

  • Not listed
📍

Where

15 sites
Cleveland Clinic
Cleveland, United States
Methodist DeBakey Heart and Vascular Center
Houston, United States
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
Aalst, Belgium
Catholic University of Leuven
Leuven, Belgium
Laboratory Signal Processing and Image, Department of Cardiology
Rennes, France
Service de Cardiologie, Hôpitaux Universitaires de Strasbourg
Strasbourg, France
Nagoya City University Graduate School of Medical Sciences
Nagoya, Japan
Ehime University
Tōon, Japan

…and 7 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy